Documents | Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | Guidance | NICE

Documents

A list of downloadable documents created during development.

Final appraisal determination

Final appraisal determination
Final appraisal determination document 29 April 2016 341.59 KB
Committee papers 29 April 2016 10.71 MB

Consultation documents published: - scope consultation

Final scope 12 October 2015 108.21 KB
Final matrix 12 October 2015 101.28 KB
NICE's response to comments on the draft scope and provisional matrix 12 October 2015 207.88 KB
Equality impact assessment (Scoping) 12 October 2015 120.59 KB

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope) 21 August 2015 114.25 KB

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope) 20 August 2015 96.96 KB

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope 25 September 2013 107.44 KB

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix 25 September 2013 104.97 KB